USMLE Step 1 & 2 Heart Failure
Last updated: May 2, 2026
Heart Failure questions are one of the highest-leverage areas to study for the USMLE Step 1 & 2. This guide breaks down the rule, the elements you need to recognize, the named traps that catch most students, and a memory aid that scales to test day. Read it once, then practice the same sub-topic adaptively in the app.
The rule
Heart failure is a clinical syndrome of impaired cardiac output or elevated filling pressures, classified by ejection fraction into HFrEF (LVEF ≤40%), HFmrEF (41-49%), and HFpEF (≥50%). The diagnostic workup centers on a clinical picture of congestion plus an elevated BNP/NT-proBNP and an echocardiogram defining EF and structural abnormalities. For HFrEF, the four pillars of guideline-directed medical therapy (ARNI/ACEi/ARB, beta-blocker, MRA, SGLT2 inhibitor) reduce mortality; for acute decompensation, IV loop diuretics are the cornerstone, with vasodilators or inotropes added based on perfusion and blood pressure.
Elements breakdown
HFrEF (Reduced Ejection Fraction)
LVEF ≤40% with signs/symptoms of heart failure; systolic dysfunction predominates.
- LVEF ≤40% on echo
- S3 gallop, displaced PMI
- Eccentric LV remodeling
- Elevated BNP/NT-proBNP
- Mortality benefit from GDMT
Common examples:
- Post-MI ischemic cardiomyopathy
- Dilated cardiomyopathy
- Chemotherapy-induced (anthracyclines)
HFpEF (Preserved Ejection Fraction)
LVEF ≥50% with HF symptoms and evidence of diastolic dysfunction or elevated filling pressures.
- LVEF ≥50% on echo
- Concentric LV hypertrophy
- Diastolic dysfunction (E/e' >14)
- Elevated BNP (often lower than HFrEF)
- Diuretics + SGLT2i; treat HTN/comorbidities
Common examples:
- Long-standing hypertension
- Obesity, diabetes, sleep apnea
- Restrictive cardiomyopathy (amyloid)
Acute Decompensated HF (Wet/Warm)
Volume overload with adequate perfusion; the most common ED presentation.
- Dyspnea, orthopnea, PND
- Bilateral crackles, JVD, edema
- Warm extremities, normal BP
- IV loop diuretic (furosemide)
- Add nitrates if hypertensive
Cardiogenic Shock (Wet/Cold)
Low output with congestion and end-organ hypoperfusion.
- Hypotension (SBP <90)
- Cool, mottled extremities
- Elevated lactate, oliguria
- Inotropes (dobutamine, milrinone)
- Consider mechanical support (IABP, Impella)
GDMT for HFrEF — The Four Pillars
Mortality-reducing therapy for chronic HFrEF; titrate to target doses.
- ARNI (sacubitril/valsartan) > ACEi/ARB
- Beta-blocker (carvedilol, metoprolol succinate, bisoprolol)
- MRA (spironolactone, eplerenone)
- SGLT2 inhibitor (dapagliflozin, empagliflozin)
Common examples:
- Add ICD if EF ≤35% after 3mo GDMT
- CRT if QRS ≥150ms LBBB
NYHA Functional Class
Symptom-based functional staging used for prognosis and trial enrollment.
- I: no symptoms with ordinary activity
- II: symptoms with ordinary activity
- III: symptoms with less-than-ordinary activity
- IV: symptoms at rest
Common patterns and traps
The Wet/Warm Trap
Most acute HF admissions are wet (congested) and warm (well-perfused). The exam writes a vignette with crackles, JVD, edema, and a normal-to-high BP — and then offers dobutamine or milrinone as a distractor. Inotropes in this setting increase arrhythmia and mortality; the answer is IV furosemide ± nitrates if hypertensive. The cold patient (cool extremities, narrow pulse pressure, lactic acidosis, oliguria) is the one who needs inotropic support.
An answer choice offering dobutamine, milrinone, or norepinephrine for a normotensive patient with crackles and edema.
The HFrEF–HFpEF Therapy Swap
The vignette names an EF (or implies it through ventricular geometry — concentric hypertrophy = HFpEF, dilated/eccentric = HFrEF), and the wrong answer applies the other category's therapy. Carvedilol with mortality benefit is HFrEF only; aggressive HTN control and SGLT2i are the HFpEF mainstays. Anchor on the EF before picking a chronic therapy.
An answer choice giving sacubitril/valsartan to a patient with EF 60% and concentric LVH, or one giving 'reassurance, no proven therapy' to a patient with EF 25%.
The Missing Precipitant
Acute decompensation almost always has a precipitant: dietary sodium load, medication non-adherence, NSAIDs, new arrhythmia (especially AFib with RVR), ischemia, infection, anemia, thyroid disease, or pulmonary embolism. The exam will dangle a clue (new ibuprofen for back pain, irregular pulse, recent URI) and ask for the next-best step — often an EKG, troponin, or TSH. Diuresing without identifying the precipitant guarantees readmission.
A vignette mentioning 'started naproxen 2 weeks ago' or 'irregularly irregular pulse on exam' where the right next step is to address the precipitant.
The BNP Confounder
BNP rises with cardiac wall stretch but is also elevated in PE, renal failure, sepsis, and old age — and it is artificially LOW in obesity (BMI >35) and on sacubitril/valsartan (which raises BNP but lowers NT-proBNP). The exam tests whether you can interpret a 'normal' BNP in an obese dyspneic patient or a 'sky-high' BNP in renal failure without HF. NT-proBNP is the cleaner marker on ARNI therapy.
A dyspneic obese patient with BNP 80 where HF is still the diagnosis, or a CKD patient with BNP 900 and no HF.
The Post-MI Cardiomyopathy
After an anterior MI with significant LV damage, EF can drop to ≤35% and the patient meets criteria for an ICD for primary prevention of sudden cardiac death — but only after 40 days post-MI and 3 months of optimized GDMT, because EF often recovers. Placing an ICD too early is a common wrong answer.
A patient 2 weeks post-MI with EF 30% where the wrong answer is 'place ICD now' instead of 'optimize GDMT and reassess EF in 3 months.'
How it works
Picture Mr. Reyes, a 68-year-old with prior anterior MI, who arrives in the ED with three days of worsening dyspnea, two-pillow orthopnea, and 4 kg weight gain. On exam he has JVD to the angle of the jaw, bibasilar crackles, an S3, and 2+ pretibial edema; his extremities are warm and his BP is 138/82. NT-proBNP is 4,200 pg/mL and echo shows EF 25% with anterior wall akinesis. He is wet and warm — give IV furosemide, continue his ARNI/beta-blocker/MRA/SGLT2i (the four pillars), and look for a precipitant (dietary indiscretion, NSAIDs, missed doses, ischemia, arrhythmia). The trap on exam is the candidate who reaches for dobutamine because the patient "has heart failure" — inotropes are reserved for the cold (hypoperfused) patient, and they increase mortality when used in warm decompensation. Notice how the EF (25%) anchors you to HFrEF and the four-pillar regimen; if his EF were 55% with the same congestion, you'd diurese the same way but skip the ARNI and add SGLT2i + treat his HTN aggressively.
Worked examples
Which of the following is the most appropriate next step in management?
- A Intravenous dobutamine infusion
- B Intravenous furosemide bolus ✓ Correct
- C Intravenous normal saline bolus
- D Emergent cardiac catheterization
Why B is correct: This is classic acute decompensated HFrEF in a wet/warm patient — congestion (JVD, crackles, edema, elevated NT-proBNP) with adequate perfusion (warm extremities, normal-to-high BP). The cornerstone therapy is an IV loop diuretic; furosemide reduces preload and relieves pulmonary edema. The clear precipitants are dietary sodium and missed diuretic dose, and there is no evidence of acute ischemia (negative troponin, no EKG changes).
Why each wrong choice fails:
- A: Dobutamine is reserved for the cold (hypoperfused) patient — cool extremities, hypotension, oliguria, elevated lactate. This patient is warm and normotensive; inotropes here increase arrhythmia and mortality without benefit. (The Wet/Warm Trap)
- C: This patient is volume-overloaded, not volume-depleted. Saline would worsen congestion and pulmonary edema. Confusing the dyspnea of HF with the dyspnea of hypovolemia/sepsis is a common reversal error.
- D: There is no evidence of acute coronary syndrome — troponin is negative, EKG shows only old changes, and the echo wall motion is unchanged from baseline. The decompensation is driven by sodium load and missed diuretic, not by new ischemia. (The Missing Precipitant)
In addition to optimizing blood pressure control and weight management, which of the following medications has the strongest evidence for reducing heart failure hospitalization in this patient?
- A Sacubitril/valsartan
- B Carvedilol
- C Empagliflozin ✓ Correct
- D Digoxin
Why C is correct: This is HFpEF: preserved EF (60%), concentric LVH, diastolic dysfunction, and clinical symptoms with mildly elevated NT-proBNP (the BNP would be even higher if not for her obesity). The EMPEROR-Preserved and DELIVER trials demonstrated that SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce HF hospitalizations and cardiovascular death in HFpEF — the first class with robust mortality/morbidity benefit in this population. SGLT2i is now a guideline Class I recommendation for HFpEF regardless of diabetes status.
Why each wrong choice fails:
- A: Sacubitril/valsartan (PARAGON-HF) failed to meet its primary endpoint in HFpEF and is not first-line. Its strong mortality benefit is in HFrEF (PARADIGM-HF), not HFpEF — applying HFrEF's pillar therapy to an HFpEF patient is the classic category swap. (The HFrEF–HFpEF Therapy Swap)
- B: Beta-blockers have not shown mortality benefit in HFpEF and may worsen exercise tolerance by limiting heart rate response. Carvedilol's mortality benefit (COPERNICUS, US Carvedilol trials) is in HFrEF, not HFpEF. (The HFrEF–HFpEF Therapy Swap)
- D: Digoxin reduces HF hospitalizations only in symptomatic HFrEF (DIG trial) and has no role in HFpEF. It also offers no mortality benefit and has a narrow therapeutic window, especially in elderly patients with even mild renal dysfunction.
Which of the following is the most appropriate next step?
- A Place an implantable cardioverter-defibrillator (ICD) for primary prevention ✓ Correct
- B Place a cardiac resynchronization therapy device (CRT-D)
- C Add ivabradine
- D Initiate amiodarone for primary prevention of sudden cardiac death
Why A is correct: This patient meets criteria for primary-prevention ICD placement: ischemic cardiomyopathy with EF ≤35%, NYHA class II symptoms, ≥40 days post-MI, and ≥3 months of optimized GDMT with persistent low EF. The SCD-HeFT and MADIT-II trials established that ICDs reduce all-cause mortality in this population by aborting sudden cardiac death from ventricular arrhythmias.
Why each wrong choice fails:
- B: CRT requires a wide QRS, ideally LBBB morphology with QRS ≥150 ms (Class I) or 120-149 ms with LBBB (Class IIa). His QRS is 110 ms with no LBBB, so he derives no benefit from biventricular pacing — only the defibrillator component is indicated.
- C: Ivabradine is added when HR remains ≥70 in sinus rhythm despite maximally tolerated beta-blocker (SHIFT trial). His HR is 64 on carvedilol, so he does not meet criteria.
- D: Amiodarone does not reduce mortality in primary prevention (SCD-HeFT showed it was no better than placebo while ICD reduced mortality). Its role is for symptomatic arrhythmias or in patients who cannot receive an ICD. (The Post-MI Cardiomyopathy)
Memory aid
Four pillars of HFrEF GDMT = 'ABCS': **A**RNI/ACEi/ARB, **B**eta-blocker, **C**ardiac MRA (mineralocorticoid antagonist — spironolactone), **S**GLT2 inhibitor. For acute HF, classify by the Forrester quadrants: **wet/warm** (diurese), **wet/cold** (diurese + inotrope), **dry/warm** (optimize GDMT), **dry/cold** (cautious fluids + inotrope).
Key distinction
HFrEF responds to neurohormonal blockade (ARNI, beta-blocker, MRA) with proven mortality benefit; HFpEF historically had no mortality-proven therapy until SGLT2 inhibitors (EMPEROR-Preserved, DELIVER) — for HFpEF, treat congestion with diuretics, add an SGLT2i, and aggressively control HTN, AFib, and obesity. Do not give a beta-blocker or ACEi to an HFpEF patient expecting the same survival benefit you'd see in HFrEF.
Summary
Heart failure is diagnosed by clinical congestion + elevated BNP + echo-defined EF; HFrEF gets the four-pillar GDMT for mortality benefit, HFpEF gets diuretics + SGLT2i + comorbidity control, and acute decompensation is managed by Forrester quadrant — diuretics for the wet, inotropes only for the cold.
Practice heart failure adaptively
Reading the rule is the start. Working USMLE Step 1 & 2-format questions on this sub-topic with adaptive selection, watching your mastery score climb in real time, and seeing the items you missed return on a spaced-repetition schedule — that's where score lift actually happens. Free for seven days. No credit card required.
Start your free 7-day trialFrequently asked questions
What is heart failure on the USMLE Step 1 & 2?
Heart failure is a clinical syndrome of impaired cardiac output or elevated filling pressures, classified by ejection fraction into HFrEF (LVEF ≤40%), HFmrEF (41-49%), and HFpEF (≥50%). The diagnostic workup centers on a clinical picture of congestion plus an elevated BNP/NT-proBNP and an echocardiogram defining EF and structural abnormalities. For HFrEF, the four pillars of guideline-directed medical therapy (ARNI/ACEi/ARB, beta-blocker, MRA, SGLT2 inhibitor) reduce mortality; for acute decompensation, IV loop diuretics are the cornerstone, with vasodilators or inotropes added based on perfusion and blood pressure.
How do I practice heart failure questions?
The fastest way to improve on heart failure is targeted, adaptive practice — working questions that focus on your specific weak spots within this sub-topic, getting immediate feedback, and revisiting items you missed on a spaced-repetition schedule. Neureto's adaptive engine does this automatically across the USMLE Step 1 & 2; start a free 7-day trial to see your sub-topic mastery climb in real time.
What's the most important distinction to remember for heart failure?
HFrEF responds to neurohormonal blockade (ARNI, beta-blocker, MRA) with proven mortality benefit; HFpEF historically had no mortality-proven therapy until SGLT2 inhibitors (EMPEROR-Preserved, DELIVER) — for HFpEF, treat congestion with diuretics, add an SGLT2i, and aggressively control HTN, AFib, and obesity. Do not give a beta-blocker or ACEi to an HFpEF patient expecting the same survival benefit you'd see in HFrEF.
Is there a memory aid for heart failure questions?
Four pillars of HFrEF GDMT = 'ABCS': **A**RNI/ACEi/ARB, **B**eta-blocker, **C**ardiac MRA (mineralocorticoid antagonist — spironolactone), **S**GLT2 inhibitor. For acute HF, classify by the Forrester quadrants: **wet/warm** (diurese), **wet/cold** (diurese + inotrope), **dry/warm** (optimize GDMT), **dry/cold** (cautious fluids + inotrope).
What's a common trap on heart failure questions?
Confusing HFrEF and HFpEF treatment
What's a common trap on heart failure questions?
Giving inotropes to a wet/warm patient
Ready to drill these patterns?
Take a free USMLE Step 1 & 2 assessment — about 25 minutes and Neureto will route more heart failure questions your way until your sub-topic mastery score reflects real improvement, not luck. Free for seven days. No credit card required.
Start your free 7-day trial